Delivery Order SPE2DR25D2009-SPE2DR26FJ2W7
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,354.16 to AmerisourceBergen Drug Corp for the supply of Mounjaro 5 mg/0.5 mL pens on November 5, 2025, with completion targeted for November 6, 2025. This firm fixed-price delivery order represents a non-competitive award and will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,990.49 to AmerisourceBergen Drug Corp for the supply of Mounjaro 5 mg/0.5 ml pens on July 31, 2025, with completion scheduled for August 1, 2025. This firm fixed-price, non-competitive delivery order represents a small-value pharmaceutical procurement executed under AmerisourceBergen's existing indefinite delivery contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,812.48 to AmerisourceBergen Drug Corp for the supply of Mounjaro 7.5 mg/0.5 mL pens on October 21, 2025, with an ultimate completion date of October 22, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters....
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $46,456.89 to AmerisourceBergen Drug Corp for the supply of Mounjaro 15 mg/0.5 mL pens. This firm fixed-price, competitively awarded delivery order was issued on September 9, 2025, with an ultimate completion date of September 10, 2025, and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. The award carries no set-aside designation, reflecting AmerisourceBergen's competitive standing...
- The Defense Logistics Agency awarded a $2,776.41 delivery order to AmerisourceBergen Drug Corp for the supply of Mounjaro 5 mg/0.5 mL pens on September 22, 2025, with completion targeted for September 23, 2025. This is a firm fixed price, non-set-aside contract with performance taking place at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a $3,228.25 delivery order on August 29, 2025, for the supply of Mounjaro 7.5 mg/0.5 ml pens with a completion date of September 2, 2025. This is a firm fixed price delivery order with no set-aside designation, meaning the award was competitively issued. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,344.41 to AmerisourceBergen Drug Corp for the supply of Mounjaro 10 mg/0.5 mL pens on September 10, 2025, with completion expected by September 11, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Mounjaro is a branded pharmaceutical product used in diabetes management,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $32,340.37 to AmerisourceBergen Drug Corp for the supply of Mounjaro 5 mg/0.5 mL pens on August 18, 2025, with an ultimate completion date of August 19, 2025. This firm fixed-price delivery order, which carries no set-aside designation, will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a competitively awarded order issued under AmerisourceBergen's existing Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,018.76 to AmerisourceBergen Drug Corp for the supply of Mounjaro 7.5 mg/0.5 mL pens on October 17, 2025, with completion targeted for October 20, 2025. This competitively awarded, non-set-aside order utilizes firm fixed pricing and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 20, 2025, for the supply of Mounjaro 10 mg/0.5 mL pens with a ceiling value of $3,434.34. This is a firm fixed-price delivery order with an ultimate completion date of October 21, 2025, and represents a non-competitive set-aside transaction. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and serves...
- SPE2DR25D2009Indefinite Delivery Contract
- SPE2DR25D2009-SPE2DR26FJ2W7Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,416.57 to AmerisourceBergen Drug Corp for the supply of Mounjaro 5 mg/0.5 mL pens on November 4, 2025, with an ultimate completion date of November 5, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and running through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly serving military and veteran healthcare systems through the DLA Medical Supply Chain. The company's extensive portfolio of federal contract awards demonstrates its capability to supply a wide range of pharmaceutical products across multiple therapeutic domains, including specialty medications, brand-name and generic drugs, vaccines, and medical supplies. Mounjaro, a diabetes medication, represents one of numerous pharmaceutical products the company delivers under its prime IDV agreement, which supports the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $17.4k | 11/4/25 |